Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 3 × Glioblastoma × tofacitinib × Clear all

Phase

Status

Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Psoriasis 6 Lymphoma, Follicular 6 Bronchiolitis Obliterans Syndrome 6 Pruritus 4 Plaque, Amyloid 1 Glioblastoma 1 Arthritis, Rheumatoid 1 Arthritis, Psoriatic 1

Interventions

Temozolomide 35 Radiotherapy 16 Lomustine 10 Bevacizumab 10 Carmustine 7 Radiation 6 Procarbazine 4 Surgical Procedures, Operative 3 Magnetic Resonance Spectroscopy 3 pembrolizumab 2 Tf-CRM107 2 Radiotherapy, Intensity-Modulated 2 Drug Therapy 2 Dihematoporphyrin Ether 2 DNA Methylation 2 Carboplatin 2 trans-sodium crocetinate 1 tofacitinib 1 sargramostim 1 rindopepimut 1 niraparib 1 marizomib 1 edotecarin 1 depatuxizumab mafodotin 1 contrast agent BR1 1 cediranib 1 carmustine, poliferprosan 20 drug combination 1 Vincristine 1 Valproic Acid 1 TVB-2640 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT05326464 2025-12-15

Tofacitinib in Recurrent GBM Patients

University of Texas Southwestern Medical Center

Phase 3 Active not recruiting

Glioblastoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡